keyword
MENU ▼
Read by QxMD icon Read
search

Intravitreal implant

keyword
https://www.readbyqxmd.com/read/29134820/pharmacokinetics-of-intravitreal-anti-vegf-drugs-in-vitrectomized-versus-non-vitrectomized-eyes
#1
Magdalena Edington, Julie Connolly, Ngaihang Victor Chong
Introduction The review aims to discuss effects of vitrectomy on pharmacokinetics of anti-vascular endothelial growth factor (anti-VEGF) agents, and attempt to provide treatment guidance. Areas Covered An Embase search was conducted using the terms 'anti-VEGF', 'pegaptanib', 'ranibizumab', 'bevacizumab', 'aflibercept', 'pharmacokinetics', 'half-life', 'clearance', 'metabolism', 'vitrectomy', 'vitrectomized'. Published data regarding the pharmacokinetic properties of the above drugs and the effect of vitrectomy in animal and human eyes was reviewed...
November 14, 2017: Expert Opinion on Drug Metabolism & Toxicology
https://www.readbyqxmd.com/read/29127949/effect-of-adding-dexamethasone-to-continued-ranibizumab-treatment-in-patients-with-persistent-diabetic-macular-edema-a-drcr-network-phase-2-randomized-clinical-trial
#2
Raj K Maturi, Adam R Glassman, Danni Liu, Roy W Beck, Abdhish R Bhavsar, Neil M Bressler, Lee M Jampol, Michele Melia, Omar S Punjabi, Hani Salehi-Had, Jennifer K Sun
Importance: Some eyes have persistent diabetic macular edema (DME) following anti-vascular endothelial growth factor (anti-VEGF) therapy for DME. Subsequently adding intravitreous corticosteroids to the treatment regimen might result in better outcomes than continued anti-VEGF therapy alone. Objective: To compare continued intravitreous ranibizumab alone with ranibizumab plus intravitreous dexamethasone implant in eyes with persistent DME. Design, Setting, and Participants: Phase 2 multicenter randomized clinical trial conducted at 40 US sites in 129 eyes from 116 adults with diabetes between February 2014 and December 2016...
November 11, 2017: JAMA Ophthalmology
https://www.readbyqxmd.com/read/29127657/real-world-cost-savings-demonstrated-by-switching-patients-with-refractory-diabetic-macular-edema-to-intravitreal-fluocinolone-acetonide-iluvien-a-retrospective-cost-analysis-study
#3
Soon W Ch'ng, Alexander J Brent, Theodoros Empeslidis, Vasileios Konidaris, Somnath Banerjee
INTRODUCTION: It is hypothesized that using fluocinolone acetonide (FAc) implants such as Iluvien for the treatment of diabetic macular edema (DME) may reduce the total number of intravitreal injections and clinic visits, resulting in an overall treatment cost reduction. The primary aim of this study is to identify the real-world cost savings achievable in a tertiary National Health Service (NHS) hospital. METHODS: A retrospective cost analysis study was conducted...
November 10, 2017: Ophthalmology and Therapy
https://www.readbyqxmd.com/read/29119239/safety-and-efficacy-of-dexamethasone-intravitreal-implant-for-treatment-of-macular-edema-secondary-to-retinal-vein-occlusion-in-chinese-patients-randomized-sham-controlled-multicenter-study
#4
Xiaoxin Li, Ningli Wang, Xiaoling Liang, Gezhi Xu, Xiao-Yan Li, Jenny Jiao, Jean Lou, Yehia Hashad
PURPOSE: The purpose of this study was to evaluate the safety and efficacy of dexamethasone intravitreal implant 0.7 mg (DEX) for treatment of macular edema associated with retinal vein occlusion (RVO). METHODS: This study was a six-month, randomized, double-masked, sham-controlled, multicenter, phase 3 clinical trial with a 2-month open-label study extension. Patients with branch or central RVO received DEX (n = 129) or sham procedure (n = 130) in the study eye at baseline; all patients who met re-treatment criteria received DEX at month 6...
November 8, 2017: Graefe's Archive for Clinical and Experimental Ophthalmology
https://www.readbyqxmd.com/read/29118706/recurrent-diabetic-macular-edema-what-to-do
#5
Rita Santos Gonçalves, Carla Teixeira, Pedro Coelho
Diabetic macular edema (DME) is a leading cause of blindness in the working population. Herein, we report the case of a patient with recurrent DME for about 6 years, uncontrolled by several medical and surgical treatments, that was successfully treated with a single sustained-release fluocinolone acetonide intravitreal implant in her right eye. The affected eye had presented a visual acuity of 2/10 and a central macular thickness of 488 µm prior to the injection. After treatment with the fluocinolone acetonide intravitreal implant, the patient's right eye presented an improvement in best corrected visual acuity to 6/10 and a reduction of central macular thickness to 198 µm...
September 2017: Case Reports in Ophthalmology
https://www.readbyqxmd.com/read/29118503/inadvertent-intralenticular-dexamethasone-implant-1-year-follow-up-and-management
#6
Cagatay Caglar
We report the case of a 72-year-old female who developed macular edema (ME) due to hemicentral retinal vein occlusion in her right eye. A dexamethasone implant was inadvertently injected into the crystalline lens. The patient was followed without repositioning of the dexamethasone implant during the 12 months. Besides, the posterior subcapsular cataract and ME had progressed significantly; hence, cataract extraction and intravitreal ranibizumab injection were performed in the same session. A three-piece intraocular lens was implanted in the sulcus with optic captured, and then intravitreal ranibizumab injection was performed...
September 2017: Oman Journal of Ophthalmology
https://www.readbyqxmd.com/read/29110201/dexamethasone-intravitreal-implant-in-diabetic-macular-edema-real-life-data-from-a-prospective-study-and-predictive-factors-for-visual-outcome
#7
Irini Chatziralli, Panagiotis Theodossiadis, Efstratios Parikakis, Eleni Dimitriou, Tina Xirou, George Theodossiadis, Stamatina Α Kabanarou
INTRODUCTION: The purpose of the study was to evaluate the long-term anatomical and functional outcomes in patients with diabetic macular edema (DME) treated with intravitreal dexamethasone implant and to determine the predictive factors for the final visual outcome. METHODS: The study included 54 patients with DME refractory to previous antivascular endothelial growth factor (anti-VEGF) who were treated with intravitreal dexamethasone implant. Predictive factors for visual outcome were assessed...
November 6, 2017: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29109896/outcomes-of-intravitreal-dexamethasone-implant-in-the-treatment-of-recalcitrant-diabetic-macular-edema
#8
Dorukcan Akıncıoğlu, Murat Küçükevcilioğlu, Ali Hakan Durukan, Seçkin Aykaş, Önder Ayyıldız, Fazıl Cüneyt Erdurman
Objectives: To investigate the efficacy and safety of intravitreal dexamethasone (OZURDEX®) implantation in patients with recalcitrant diabetic macular edema. Materials and Methods: This is a retrospective non-randomized study of patients who underwent intravitreal dexamethasone implantation for recalcitrant diabetic macular edema. Main outcome measures included changes in best corrected visual acuity (BCVA), central macular thickness (CMT), and incidence of ocular side effects...
October 2017: Turkish Journal of Ophthalmology
https://www.readbyqxmd.com/read/29108392/cauterization-of-ozurdex-wound-for-the-prevention-of-scleral-leakage-in-vitrectomized-eyes
#9
Claudio Furino, Nicola Recchimurzo, Francesco Boscia, Giovanni Alessio
PURPOSE: To study if cauterization of the scleroconjuctival wound secondary to intravitreal dexamethasone implant in vitrectomized eyes is effective to avoid scleral leakage and hypotony. METHODS: A total of 35 vitrectomized eyes of 35 consecutive patients with macular edema who underwent a single intravitreal dexamethasone implant injection in the operating room at the Eye Clinic of the University of Bari, Italy, from 2013 to 2017 were retrospectively reviewed...
October 31, 2017: European Journal of Ophthalmology
https://www.readbyqxmd.com/read/29098101/a-new-side-effect-of-intravitreal-dexamethasone-implant-ozurdex%C3%A2
#10
Erdem Eris, Gurkan Erdogan, Irfan Perente, Gokhan Demir, Burcin Kepez Yildiz, Ebru Demet Aygit
Dexamethasone implant, 0,7 mg (Ozurdex, Allergan, Inc., Irvine, CA, USA), is drug mostly used in the treatment of the diabetic macular edema and edema related to retinal vein occlusion. By reporting this case we aimed to report a new side effect of 0.7 mg intravitreal dexamethasone implant that has not been reported in the literature before.
2017: Case Reports in Ophthalmological Medicine
https://www.readbyqxmd.com/read/29062594/new-drugs-and-new-posterior-delivery-methods-in-cme
#11
João Rafael de Oliveira Dias, Renata Portella Nunes, Raquel Goldhardt
PURPOSE: To discuss the characteristics, indications and adverse events (AEs) of sustained-release corticosteroid devices for the treatment of cystoid macular edema (CME). RECENT FINDINGS: Ozurdex® is approved for the treatment of diabetic macular edema (DME), retinal vein occlusion related-CME and noninfectious posterior uveitis (NIPU). It releases dexamethasone over a maximum period of 6 months making repeated intravitreal injections necessary for recurrent CME...
June 2017: Current Ophthalmology Reports
https://www.readbyqxmd.com/read/29050190/-current-research-of-sympathetic-ophthalmia
#12
Y Di, J J Ye
Sympathetic ophthalmia (SO) is a rare, bilateral, non-necrotizing, granulomatous uveitis that usually occurs after open ocular injury or intraocular surgery. The pathophysiology is not clearly understood, but generally SO is an immediate hypersensitivity mediated by T lymphocytes which are related to ocular tissue antigens. The main histopathological features are granulation tissues composed of lymphocytes, macrophages and multinucleated giant cells. The clinical manifestations are different from person to person, which might be mild or severe...
October 11, 2017: [Zhonghua Yan Ke za Zhi] Chinese Journal of Ophthalmology
https://www.readbyqxmd.com/read/29037464/-ocular-sarcoidosis-what-the-internist-should-know
#13
P Sève, L Kodjikian, Y Jamilloux
Sarcoidosis is one of the leading causes of inflammatory eye disease. Any part of the eye and its adnexal tissues can be involved. Uveitis and optic neuropathy are the main manifestations, which the internists face. This review reports the state of knowledge for these two ocular involvements and proposes an assessment-algorithm for sarcoidosis in patients with suspected sarcoid uveitis. Two groups of patients with sarcoid uveitis can be distinguished: one young and multiethnic group in which ophthalmological findings are various and another group of elderly Caucasian women with mostly chronic posterior uveitis...
October 13, 2017: La Revue de Médecine Interne
https://www.readbyqxmd.com/read/29032109/early-response-to-intravitreal-dexamethasone-implant-therapy-in-diabetic-macular-edema-may-predict-visual-outcome
#14
Hasenin Al-Khersan, Seenu M Hariprasad, Jay Chhablani
PURPOSE: To determine whether early visual acuity response to intravitreal dexamethasone implant therapy in diabetic macular edema (DME) is associated with long-term outcome. DESIGN: Retrospective case series METHODS: Multicenter (eight sites) retrospective review of medical records of eyes with DME treated with 0.7mg intravitreal dexamethasone implant and minimum eighteen-month follow-up. One hundred and two eyes were included. Eyes with vitroretinal interface abnormalities or that had undergone vitrectomy were excluded...
October 12, 2017: American Journal of Ophthalmology
https://www.readbyqxmd.com/read/29027061/scleral-fixated-intraocular-lens-implantation-with-a-modified-z-suture-technique
#15
Erdem Dinç, Mustafa Vatansever, Özer Dursun, H Görkem Markirt, Bahri Aydın, Ayça Yılmaz, Ufuk Adıgüzel
PURPOSE: To evaluate visual outcomes and complications in scleral fixated intraocular lens (IOL) implantation with the modified Z-suture technique. MATERIALS AND METHODS: Thirty-five eyes of 35 patients (20 male, 15 female) were included in the study. Patients underwent scleral fixated IOL implantation using the modified Z-suture technique and were followed in terms of visual acuity and complications. RESULTS: Mean postoperative follow-up time was 12...
October 13, 2017: International Ophthalmology
https://www.readbyqxmd.com/read/29020496/clinical-outcomes-of-adjunctive-sustained-release-intravitreal-dexamethasone-implants-in-tuberculosis-associated-multifocal-serpigenoid-choroiditis
#16
Lubhani Jain, Krushna Gopal Panda, Soumyava Basu
PURPOSE: To analyze the safety and efficacy of sustained-release intravitreal dexamethasone implant (Ozurdex) in management of TB-associated multifocal serpiginoid choroiditis (MSC). METHODS: Retrospective review of TB-associated MSC patients, treated with anti-TB therapy (ATT) and adjunctive intravitreal Ozurdex. RESULTS: Nine eyes of six patients were included. Four patients required Ozurdex implant for progressive or new lesions following ATT and two for additional systemic contraindications to corticosteroids - hyperglycemia and uncontrolled hypertension, respectively...
October 11, 2017: Ocular Immunology and Inflammation
https://www.readbyqxmd.com/read/29016454/intraocular-dexamethasone-implant-position-in-situ-and-ocular-hypertension
#17
Aditya Sudhalkar, Laurent Kodjikian, Jay Chhablani, Deepak Bhojwani, Abhay Vasavada
PURPOSE: To determine the association between the dexamethasone implant position in the vitreous cavity and ocular hypertension (OHT). METHODS: Retrospective review of patients with at least one intravitreal dexamethasone implant injection between 2012 and 2016. Patients who had a minimum follow-up for 6 months and documented evidence of the implant position were included in the study. Steroid responders, glaucoma patients, vitrectomized eyes, and eyes with liquefied vitreous were excluded...
October 9, 2017: Retina
https://www.readbyqxmd.com/read/28992424/long-term-outcome-of-intravitreal-bevacizumab-followed-by-ahmed-valve-implantation-in-the-management-of-neovascular-glaucoma
#18
Rajen Tailor, Matt T Kinsella, Jonathan C Clarke
BACKGROUND: To report the outcome of intravitreal Bevacizumab followed by Ahmed valve implantation in the management of neovascular glaucoma in a patient group with extended follow-up. METHODS: The records of 16 patients (18 eyes) with neovascular glaucoma refractory to medical therapy who presented to a single surgeon between 2006-2008 were reviewed. Patients received pan-retinal photocoagulation and then intravitreal Bevacizumab followed by Ahmed valve implantation...
October 9, 2017: Seminars in Ophthalmology
https://www.readbyqxmd.com/read/28991865/intraoperative-injection-of-intravitreal-dexamethasone-implant-using-a-vitrectomy-trocar-assisted-technique
#19
Sami H Uwaydat, Hans Wang, Ahmed B Sallam
No abstract text is available yet for this article.
October 5, 2017: Retina
https://www.readbyqxmd.com/read/28991343/endophthalmitis-following-pediatric-cataract-surgery-an-international-pediatric-ophthalmology-and-strabismus-council-global-perspective
#20
Almutez M Gharaibeh, Eedy Mezer, Luis H Ospina, Tamara Wygnanski-Jaffe
PURPOSE: To compile international data on the risk factors, diagnosis, and treatment of endophthalmitis following pediatric cataract surgery. METHODS: An e-mail containing a link to an online survey was sent to all members of the American Association for Pediatric Ophthalmology and Strabismus. The questionnaire examined the incidence, risk factors, treatment, outcomes, and prophylaxis of endophthalmitis following pediatric cataract surgery around the world. RESULTS: Two hundred thirty-seven ophthalmologists answered the questionnaire...
October 9, 2017: Journal of Pediatric Ophthalmology and Strabismus
keyword
keyword
99632
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"